Your Source for Venture Capital and Private Equity Financings

Mersana Therapeutics Grabs $10M

2012-04-18
CAMBRIDGE, MA, Drug developer, has raised $10 million in venture capital, according to a new securities filing with the SEC.
Mersana Therapeutics, a drug developer, has raised $10 million in venture capital, according to a new securities filing with the SEC. Seven separate investors participated in the offering.

Mersana engineers novel drug conjugates that maximize the potential of new and established therapeutic classes. Our technology harnesses the power and synergy of nanotechnology, biologics and small molecules.

Mersana is advancing its own pipeline of next-generation drugs with best-in-class potential to address unmet needs and improve patient outcomes in multiple oncology indications. Utilizing our technology, we are developing a portfolio of next-generation antibody-drug conjugates (ADC) with superior properties not found with current ADC technologies. Our clinical pipeline consists of two cancer therapeutics with blockbuster potential. XMT-1001 is a potentially best-in-class novel "tecan" conjugate that is currently being investigated in a Phase 1b extension trial in patients with lung cancers. XMT-1107 is a first-in-class anti-angiogenic conjugate with a unique mechanism of action that is currently in a Phase 1 trial in patients with refractory, advanced solid tumors. XMT-1107 was licensed to Teva on a worldwide basis except for Japan, where Mersana elected to retain rights. These clinical candidates reflect the successful application of our unique conjugation system.
(c)2011-2020 by Massinvestor, Inc. For contact info, please check out our about page.
>> Click here for in-depth research on 9,000 startups and 5,000 VC investors


Featured Reading